reason report
bottom line view high growth research tool
engin consist high margin consum busi
posit drive growth key end-market preclin
discoveri translat research cell gene therapi liquid
impress organ growth upsid protein scienc
dxg diagnost genom segment deliv growth
also benefit revers oem eu order time issu
oper margin saw pressur exosomedx invest
currenc believ margin like improv throughout
expect fy op margin end roughli flat exosom epi
deliv benefit bill begin decemb
still believ long-term outlook depend
continu growth core protein platform antibodi busi
advanc cell diagnost acd rnascop deliv upsid
long term continu remain bullish build cell
gene therapi workflow gmp manufactur practic
protein facil -- combin deliv yr
maintain op rate pt move
stronger-than-expect quarter core busi continu
cell gene therapi workflow remain opportun
long-term revenu upsid broken ground new
manufactur facil abl deliv
gmp protein option expand capac
time manag note gmp protein sale
indic robust custom demand remain focus
build capabl cell therapi workflow given alreadi
number piec workflow includ b-mogen non-vir
vector antibodi t-cell activ use technolog acd
profil cell therapi activ gmp protein cell expans assay
antibodi qc ella platform protein detect monitor
protein scienc segment continu deliv
core antibodi protein busi grew mid-teen
quarter diversifi growth across product region china grew
eu bounc back quarter aid larg
pharma order manag still point hsd growth rang
eu simpl western system instal ww
consum growth revamp websit increas
digit market spend help recent strength antibodi busi
longer term see segment benefit gmp grade protein
cell therapi custom could doubl protein busi year
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
compani inform svb leerink llc research
revenu ep exclud charg amort intang
dxg segment strong epi test reimburs flow
dxg grew organ ahead street
expect oem order time posit legaci
glucos control busi stabil rna scope deliv anoth
quarter recal local coverag determin lcd
epi test final earli oct bill begin dec
expect lag also bill prior year test
perform although manag settl far look-
back goe epi test volum grew y/i manag expect
vol growth aid reimburs come quarter
help address roughli unnecessari prostat biopsi
us still much high growth high margin consum
lever stori strong cash flow profil manag
highlight us number growth driver across busi rang
advanc cell diagnost acd protein platform core
antibodi busi -- suggest product diversif across
product line gross margin oper margin reach
longer term remain key long-term growth outlook
model chang strong organ growth quarter
moder rais revenu organ growth estim
 ep move slightli lower
om margin bit lighter expect
remain confid flat y/i om target full year
ep move
rate share outperform price target view
posit given nimbl research tool engin favor
consum profil sale continu deliv high-singl digit low-doubl
digit organ growth target track record success execut inorgan
growth via strateg acquisit pois grow highli fragment research tool
industri diagnost dx tech acd acquisit believ continu
drive signific upsid biopharma account clinic diagnost longer term
believ exosom add growth next year receiv medicar coverag
commerci payer
 believ continu pick differenti attract asset high
gross margin fill adjac expand posit consum
nine acquisit last three year given uniqu profil compani among
research tool univers increasingli posit tech outlook
rate outperform given uniqu high margin busi profil consist
consum instrument outlook diversifi across life
scienc tool also lever grow area diagnost next year
hope deliv revenu number believ conserv given
growth driver also see
bio-techn high growth protein scienc deliv mid-teen organ compound-annual-growth-rate
drive simpleplex technolog deeper protein reagent biopharma
pois succeed plan grow inorgan highli fragment research
tool diagnost sector pick uniqu differenti attract asset high
gross margin fill adjac expand posit consum
time dont expect compani lever beyond debt/ebitda believ
gener dri powder next year given current growth rate
expect laid investor day
see opportun gene cell therapi workflow potenti deliv
conserv longer term build gmp facil scale capabl
cell gene therapi manufactur recal also acquir b-mogen non-vir
vector technolog remain integr drive growth gene cell therapi portfolio
tech acd acquisit alreadi deliv believ continu deliv mid-
teen growth longer term acd well entrench translat research biopharma
believ next step come inclus acd routin patholog diagnost
significantli larger market vs current research use ruo posit
tech exosom dx acquisit taken longer deliv exosom dx see
power technolog strong ip like benefit longer term though
deliv lacklust result given limit reimburs exosom dx epi test
believ final lcd exosom deliv stronger result
medicar commerci reimburs improv eventu reach like
exceed estim laid manag
confid manag team led ceo charl kummeth key tech
success last three year believ like continu manag execut
portfolio long-rang plan laid investor day
current trade ev/ebitda believ stock
abl trade ev/ebitda given growth profil consumables-heavi portfolio
valuat methodolog appli ev/ebitda estim yield
price target peer group consist
pt base calendar year estim order arriv like-for-lik comparison
peer group base fiscal year end june
could face number risk includ
downturn biopharma fund regul chang fda lead dramat
chang profit drug compani drive compani reduc spend
anticip poor return invest
declin nih fund due chang polit leadership period flat
declin alloc research spend could sever curtail abil
compani grow despit high consum portfolio
citat includ type citat restrict compani abil produc
diagnost reagent extend period time forc diagnost instrument provid
switch away bio-techn reagent could lead sustain declin diagnost
increas competit merck sigma-aldrich bio-rad vwr could also lead
declin tech sale addit increas competit abcam antibodi
manufactur market could also impact tech sale competit also aris
intern china key growth market local reagent provid
potenti suppli reagent lower price impact tech margin
higher dollar could dampen ou demand tech product manufactur
restrict trade certain countri china asian countri could also
dramat reduc need product countri dramat fx chang includ
sudden declin uk pound sterl could impact compani revenu
exposur uk european headquart also locat uk
good sold
amort intang
total expens incom
net incom continu op
ep incl stock-bas comp closer comp peer
sg sale
 sale
oper expens sale
compani report svb leerink estim
